Atomoxetine versus placebo with fMRI assessment in children and adolescents with dyslexia and/or ADHD

Phase 4 trial of atomoxetine in dyslexia and attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change From Baseline to Endpoint in Functional Magnetic Resonance Imaging (fMRI) Activation in Participants With Dyslexia Alone (Pseudoword Rhyming and Semantic-category), fMRI activation during Stroop attention task and 1 more.